William Blair Sticks to Its Buy Rating for Microstrategy (MSTR)

William Blair analyst Kamil Mielczarek maintained a Buy rating on Microstrategy (MSTR – Research Report) yesterday. The company's shares closed last Thursday at $625.01. According to TipRanks.com, Mielczarek is ranked #4936 out of 7609 analysts. Currently, the analyst consensus on Microstrategy is a Hold with an average price target of $583.33. See today’s analyst top recommended stocks >> The company has a one-year high of $1315.00 and a one-year low of $115.87. Currently, Microstrategy has an average volume of 808.7K. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. MicroStrategy, Inc. engages in the provision of enterprise analytics and mobility software. It designs, develops, markets, and sells software platform through licensing arrangements and cloud-based subscriptions and related services. Its flagship platform, MicroStrategy 10, consists of the MicroStrategy Analytics, MicroStrategy Mobile, and Usher brands. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989 and is headquartered in Vienna, VA. Read More on MSTR: BTIG Believes Misonix (MSON) Still Has Room to Grow William Blair Reaffirms Their Hold Rating on SPS Commerce (SPSC) Cubesmart (CUBE) Gets a Buy Rating from BMO Capital New Sell Rating for International Paper Co (IP), the Energy Giant Chemours Company (CC) Received its Third Buy in a Row The post William Blair Sticks to Its Buy Rating for Microstrategy (MSTR) appeared first on TipRanks Financial Blog.

William Blair analyst Kamil Mielczarek maintained a Buy rating on Microstrategy (MSTR – Research Report) yesterday. The company's shares closed last Thursday at $625.01.

According to TipRanks.com, Mielczarek is ranked #4936 out of 7609 analysts.

Currently, the analyst consensus on Microstrategy is a Hold with an average price target of $583.33.

The company has a one-year high of $1315.00 and a one-year low of $115.87. Currently, Microstrategy has an average volume of 808.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MicroStrategy, Inc. engages in the provision of enterprise analytics and mobility software. It designs, develops, markets, and sells software platform through licensing arrangements and cloud-based subscriptions and related services. Its flagship platform, MicroStrategy 10, consists of the MicroStrategy Analytics, MicroStrategy Mobile, and Usher brands. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989 and is headquartered in Vienna, VA.

Read More on MSTR:

  • BTIG Believes Misonix (MSON) Still Has Room to Grow
  • William Blair Reaffirms Their Hold Rating on SPS Commerce (SPSC)
  • Cubesmart (CUBE) Gets a Buy Rating from BMO Capital
  • New Sell Rating for International Paper Co (IP), the Energy Giant
  • Chemours Company (CC) Received its Third Buy in a Row

The post William Blair Sticks to Its Buy Rating for Microstrategy (MSTR) appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

What's Your Reaction?

like
0
dislike
0
love
0
funny
0
angry
0
sad
0
wow
0

Next Article

Analysts Offer Insights on Healthcare Companies: Bristol Myers (BMY) and Capital Senior Living (CSU)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol Myers (BMY – Research Report) and Capital Senior Living (CSU – Research Report). Bristol Myers (BMY) Barclays analyst Carter Gould maintained a Hold rating on Bristol Myers on July 28 and set a price target of $71.00. The company's shares closed last Thursday at $68.15, close to its 52-week high of $68.99. According to TipRanks.com, Gould is a 3-star analyst with an average return of 5.2% and a 44.9% success rate. Gould covers the Healthcare sector, focusing on stocks such as Reata Pharmaceuticals, Travere Therapeutics, and Eli Lilly & Co. Bristol Myers has an analyst consensus of Moderate Buy, with a price target consensus of $73.50, representing a 6.5% upside. In a report released yesterday, Morgan Stanley also maintained a Hold rating on the stock with a $71.00 price target. See today’s analyst top recommended stocks >> Capital Senior Living (CSU) In a report issued on July 28, Steven Valiquette from Barclays maintained a Sell rating on Capital Senior Living, with a price target of $23.00. The company's shares closed last Thursday at $30.75. According to TipRanks.com, Valiquette is a 3-star analyst with an average return of 2.3% and a 56.1% success rate. Valiquette covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Bright Health Group, and AmerisourceBergen. Currently, the analyst consensus on Capital Senior Living is a Moderate Sell with an average price target of $23.00. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Read More on BMY: William Blair Sticks to Its Buy Rating for Microstrategy (MSTR) BTIG Believes Misonix (MSON) Still Has Room to Grow William Blair Reaffirms Their Hold Rating on SPS Commerce (SPSC) Cubesmart (CUBE) Gets a Buy Rating from BMO Capital New Sell Rating for International Paper Co (IP), the Energy Giant The post Analysts Offer Insights on Healthcare Companies: Bristol Myers (BMY) and Capital Senior Living (CSU) appeared first on TipRanks Financial Blog.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol Myers (BMY – Research Report) and Capital Senior Living (CSU – Research Report).

Bristol Myers (BMY)

Barclays analyst Carter Gould maintained a Hold rating on Bristol Myers on July 28 and set a price target of $71.00. The company's shares closed last Thursday at $68.15, close to its 52-week high of $68.99.

According to TipRanks.com, Gould is a 3-star analyst with an average return of 5.2% and a 44.9% success rate. Gould covers the Healthcare sector, focusing on stocks such as Reata Pharmaceuticals, Travere Therapeutics, and Eli Lilly & Co.

Bristol Myers has an analyst consensus of Moderate Buy, with a price target consensus of $73.50, representing a 6.5% upside. In a report released yesterday, Morgan Stanley also maintained a Hold rating on the stock with a $71.00 price target.

Capital Senior Living (CSU)

In a report issued on July 28, Steven Valiquette from Barclays maintained a Sell rating on Capital Senior Living, with a price target of $23.00. The company's shares closed last Thursday at $30.75.

According to TipRanks.com, Valiquette is a 3-star analyst with an average return of 2.3% and a 56.1% success rate. Valiquette covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Bright Health Group, and AmerisourceBergen.

Currently, the analyst consensus on Capital Senior Living is a Moderate Sell with an average price target of $23.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BMY:

  • William Blair Sticks to Its Buy Rating for Microstrategy (MSTR)
  • BTIG Believes Misonix (MSON) Still Has Room to Grow
  • William Blair Reaffirms Their Hold Rating on SPS Commerce (SPSC)
  • Cubesmart (CUBE) Gets a Buy Rating from BMO Capital
  • New Sell Rating for International Paper Co (IP), the Energy Giant

The post Analysts Offer Insights on Healthcare Companies: Bristol Myers (BMY) and Capital Senior Living (CSU) appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.